Articles tagged with Ovarian Cancer
IU researchers aim to capitalize on human genome data and powerful bioinformatics approaches to develop better therapies for ovarian and breast cancer patients. The study will focus on genetic and molecular consequences of DNA modifications to improve predictive models.
Research found ovarian cancer rates levelling across Europe, with declining incidence and mortality rates in northern countries, particularly among younger age groups. In contrast, southern and eastern European countries saw increasing cancer incidence and mortality rates.
A new protein, Rab25, has been associated with increased aggressiveness in both breast and ovarian cancers. Low levels of Rab25 protein expression were found to be linked to better clinical outcomes, with patients experiencing higher survival rates when tumors expressed low levels of the protein.
A study of supportive-expressive group therapy for women with BRCA1 or 2 gene mutations found improvements in anxiety, depression, and decision-making. The therapy helped women weigh treatment choices by exploring feelings and perspectives.
A meta-analysis of RCT data found that patients receiving adjuvant chemotherapy had a lower risk of death and recurrence than those not receiving chemotherapy. Women with optimally staged stage I ovarian cancer may have an excellent prognosis without adjuvant chemotherapy.
Fox Chase Cancer Center researchers have identified hypermethylation of BRCA1 and RASSF1A genes as a potential target for detecting ovarian cancer in blood. The study found that 82% of patients with ovarian cancer had hypermethylated genes in their blood DNA, making it a promising diagnostic tool.
Researchers found that a blood test, CA125, was 2.6 times more accurate than CT scans in predicting patient survival. The study suggests that tumor-marker guided response criteria like CA125 may be superior to imaging-based response criteria in predicting treatment outcomes.
In a breakthrough study, researchers found that dendritic cells, a type of immune cell, can be co-opted by tumors to promote angiogenesis and tumor growth. The study suggests a new approach to fighting solid tumors by targeting the interaction between angiogenesis and the immune response.
Researchers found that ovarian cancer tumors lack response to antiestrogens due to decreased ER beta expression, which can lead to increased cell proliferation and apoptosis. The reintroduction of ER beta in cancer cells induced apoptosis, suggesting its regulatory functions in controlling ovarian cancer growth and motility.
Researchers identify three biomarkers from serum proteomic analysis that correctly identified 74% of early-stage ovarian cancers, improving detection capabilities. The test combines these markers with CA125 for enhanced accuracy.
Researchers have identified a potential biomarker for ovarian cancer using a blood test that accurately predicts the presence of the disease in 93% of cases. The study suggests that lysophospholipids, found in high levels in most ovarian cancer patients, may be used to develop an early detection strategy for this devastating disease.
Researchers are collecting blood samples from hundreds of women to validate the novel approach. The test has received worldwide attention due to its potential for early detection and high survival rates. If successful, it could save thousands of lives annually.
Researchers found that women with ovarian cancer typically experience symptoms 20-30 times per month and have more severe and recent-onset symptoms. In contrast, women with benign masses or controls have fewer and milder symptoms.
A study of 60 Korean women with breast cancer found a high rate of genetic mutations in BRCA1 and BRCA2 genes. The average age of diagnosis was 40-50 years old, which is younger than in the US population. The study suggests different genetic and environmental factors may be at play for Korean patients diagnosed at a young age.
A study by Johns Hopkins Medicine found that nearly half of ovarian cancer surgeries in Maryland were performed by low-volume surgeons, those with four or fewer cases per year. High-volume surgeons, who perform more than 10 cases per year, are more likely to accurately assess disease stage and increase survival rates.
The US Preventive Services Task Force recommends against routine ovarian cancer screening due to no evidence that it reduces mortality. In contrast, they support regular eye exams for children under 5 to detect amblyopia and other causes of visual impairment. Early detection can improve visual acuity and prevent long-term harm.
A recent study found that coronal reformatted images from 16-MDCT can change overall readings in 83% of cases with ovarian cancer. The study suggests that radiologists should view both axial and coronal images together to accurately stage the disease.
Researchers examined 45 primary ovarian carcinoma samples and found that 40% had decreased or complete loss of Rb2 protein expression. The study suggests Rb2's role in ovarian carcinogenesis and potential clinical applications for detecting and treating cancer.
A Medical College of Georgia study aims to identify specific protein markers in the blood that indicate how ovarian cancer responds to therapy. By analyzing changes in protein expression over time, researchers hope to develop a better understanding of the disease process and create more effective screening tests.
Researchers discovered structural changes in ovary lining cells and higher levels of Bcl-2 protein in women with ovarian cancer. These findings suggest potential early detection methods for the disease.
New nanotech imaging techniques offer improved precision in detecting tumors, including lymphatic drainage imaging for breast cancer, and molecular fingerprints for prostate and ovarian cancer. These advancements aim to improve diagnosis and treatment options for cancer patients.
Researchers found that COX-2 over-expression promotes loss of basement membrane in ovarian epithelium cells, leading to disorganization and cancer. The study suggests COX-2 inhibitors may prevent cancer development by reducing basement membrane loss.
OHSU scientists successfully transplanted ovarian tissue into monkeys, allowing the return of hormone cycles and egg production. The procedure may lead to new methods for preserving fertility in young cancer survivors.
Researchers found that retinoblastoma survivors are at higher risk of epithelial cancers such as esophagus, stomach, colon, lung, breast, cervix, or prostate, despite low radiation therapy. High folate intake is associated with a lower risk of ovarian cancer, especially among women who consume alcohol.
Phenoxodiol, a chemo-sensitizer, has shown encouraging results in treating late-stage ovarian cancer. The study found 25% response rates and synergy with chemotherapy, suggesting potential benefits for patients.
The University of Pennsylvania School of Medicine has established a first-of-its-kind peer-support helpline for individuals concerned about hereditary breast and ovarian cancer. The helpline provides direct access to trained volunteers who offer emotional support, referrals, and information on genetic counseling and risk management.
The study found that patients treated with DOXIL had a median overall survival of 63 weeks, compared to 60 weeks with topotecan. Additionally, DOXIL showed significant advantages in progression-free survival and median PFS for platinum-sensitive patients.
Researchers found correlations between cellular features and cancer development in prostate and ovarian cancers. Prostatic intraepithelial neoplasia may be a significant target for prevention strategies.
Women with BRCA1 and BRCA2 mutations have a high risk of developing breast cancer, but exercising during adolescence and maintaining a healthy weight may slow its onset. The study found that these lifestyle factors were protective regardless of birth year or family history.
A new biomarker for ovarian and uterine carcinomas has been identified, associated with poor clinical outcome. L1 glycoprotein was found in 46 of 58 ovarian cancers and 20 of 72 uterine cancers, indicating a bad prognostic factor for patient survival.
The Annual Report to the Nation on Cancer statistics shows stabilized cancer rates. A study found carboplatin-paclitaxel is better tolerated in ovarian cancer patients than cisplatin-paclitaxel. Another study linked blood transfusions with HHV-8 seropositivity, while HPV status may predict cervical lesion prognosis
A recent study found that the TGFBR1*6A gene is associated with a 26% increase in cancer risk, particularly for breast, ovarian, and colon cancers. The study's findings suggest that genetic testing and counseling can help identify individuals at high risk and provide targeted prevention strategies.
Researchers found that postmenopausal women with a higher body mass index have an increased risk of breast cancer due to elevated estrogen levels. In contrast, heavier men under age 60 or those with family history of prostate cancer may experience lower risks of developing the disease.
Researchers have identified new serum biomarkers for ovarian cancer, which may be used in conjunction with existing methods such as CA125 marker and ultrasound to improve diagnosis. These newly discovered markers show promise in detecting the disease at an early stage, leading to better treatment outcomes.
Researchers found a slightly increased risk of ovarian cancer in women with endometriosis, with a half-life increase and higher risks for younger women. In contrast, the risk of cervical cancer was reduced by roughly a third. Further investigation is needed to understand the connection between endometriosis and cancer.
Studies on prophylactic surgery for women with BRCA1/2 mutations show a significant reduction in breast and ovarian cancer risk. However, potential biases in study designs, such as confounding by indication and familial-event bias, may lead to underestimation of risk reduction.
A new biomarker, HE4, has been identified as a potential tool for early detection of ovarian cancer. The molecule is secreted into the blood and its presence can be detected in simple clinical tests.
The European Society for Medical Oncology (ESMO) presented a new drug, ET743, which has shown promising results in treating advanced ovarian cancer. In a clinical trial, the drug reduced tumors in 47% of patients, with some experiencing complete responses.
A study of 800 women with relapsing ovarian cancer found that combination chemotherapy showed a modest survival benefit compared to platinum-based chemotherapy alone. Women assigned combination therapy survived for an average of five months more than those given platinum therapy.
Two studies found that paclitaxel-based chemotherapy regimens and mini-transplants can help preserve ovarian function in younger patients. The paclitaxel regimen improved a woman's chance of regaining her ovarian function, while mini-transplants showed better results in preserving ovaries compared to high-dose chemo.
Researchers have discovered a second mechanism by which LPA promotes ovarian tumor growth through increased cyclin D1 protein levels. Additionally, the identification of PEP, a peptide fragment with vasopermeability activity, may help reduce toxicity in cancer immunotherapy. A new study also suggests that p16 inhibitors play a role in ...
Researchers at Cedars-Sinai Medical Center found that patients with hereditary BRCA-associated ovarian cancer respond better to chemotherapy, leading to improved survival. The study suggests that platinum-based chemotherapy may be more effective for these patients, and this finding may enable physicians to better plan treatment.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
A new study found that strengthening upper leg muscles does not protect against knee osteoarthritis and may even worsen it in people with certain knee conditions. Researchers also discovered that one-third of cancer patients who died received chemotherapy in their last six months of life.
A new generation of medical treatment is being driven by proteomics, enabling early detection of cancer and personalized therapy. The technology uses multiple high-resolution serum proteomic patterns to detect disease, with 85% accuracy in diagnosis.
Researchers found that 68% of invasive low-grade ovarian tumors and 61% of precancerous lesions carried one of the three common mutations in BRAF or KRAS. Blocking KRAS-BRAF signaling may provide more effective therapy for these cancers, which generally do not respond well to conventional chemotherapy.
Researchers at Fox Chase Cancer Center developed a transgenic mouse model of epithelial ovarian cancer, allowing scientists to study the disease's progression from early stages. The model has the potential to facilitate advances in early detection and treatment of ovarian cancer.
Researchers at Vanderbilt University Medical Center found that COX-1, not COX-2, is expressed in epithelial ovarian cancer tissue samples. This discovery may lead to the development of new treatments for ovarian cancer by blocking both COX-1 and COX-2.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
Researchers at Johns Hopkins Medicine conducted a study on combined PET-CT for detecting ovarian cancer, finding that the combination showed high sensitivity (73.6%) and specificity (100%) rates. This improved detection accuracy compared to using PET scans alone.
Researchers used digital SNP analysis to detect ovarian cancer in 87% of early-stage and 95% of late-stage patients, with high total DNA amounts found in most cancer cases. The test holds promise for improved detection in a wide range of cancers.
Two new studies published in the Journal of the National Cancer Institute identified key risk factors for classical Kaposi's sarcoma and found that smoking may decrease the risk of this disease. Meanwhile, research on leptin suggests it controls breast cancer cell proliferation. Additionally, a potential screening tool for ovarian canc...
A new study published in Obstetrics and Gynecology found that aspirin inhibited ovarian tumor cell growth by as much as 68 percent. Combining aspirin with a monoclonal antibody targeting the HER-2/neu protein resulted in an even greater suppression of growth, decreasing cancer cell growth by 84 percent.
Research studies found small but statistically significant increases in cancer risks among BRCA1 mutation carriers, including colon, liver, pancreatic, and cervical cancers. Additionally, male BRCA1 mutation carriers had a slightly elevated risk of prostate cancer.
A study by Nikola Pavletich and colleagues reveals that BRCA2 protein binds to damaged DNA, repairing it. This discovery sheds light on the mechanism of breast cancer development and opens new avenues for treatment strategies.
Researchers at Memorial Sloan-Kettering Cancer Center have uncovered the function of the BRCA2 protein, which interacts directly with DNA to repair genetic damage. This new understanding sheds light on how mutations in the BRCA2 gene contribute to inherited breast and ovarian cancers.
A review highlights the association between excess body weight and increased cancer risk, particularly in colon, breast, endometrium, oesophagus, and kidney. The study suggests that alterations in hormone metabolism may play a role in this link, emphasizing the importance of weight management for cancer prevention.
Research identifies young women with breast cancer at increased risk of ovarian cancer, including those with BRCA1 and BRCA2 gene mutations. The study suggests that these women may benefit from prophylactic oophorectomy or counseling.
A new study from the International Collaborative Ovarian Neoplasm (ICON) Collaborators found that paclitaxel plus carboplatin produces similar effectiveness to other treatments for women with ovarian cancer, but with more serious side effects. Carboplatin may be considered a preferred treatment option due to its better toxicity profile.
A study found that hereditary BRCA1 and BRCA2 ovarian cancers have similar gene expression profiles to sporadic ovarian cancers. The research suggests shared molecular mechanisms between hereditary and sporadic ovarian carcinogenesis exist.